Karuna, Cerevel might be just the start of psychiatry drug M&A

Karuna, Cerevel might be just the start of psychiatry drug M&A

Source: 
BioPharma Dive
snippet: 

With two biotech buyouts, schizophrenia drugs appear back on pharma’s radar. Deal documents suggest others besides Bristol Myers and AbbVie may be looking.